In Depth: Could Pfizer’s Drug Paxlovid Change China’s Covid Policy?

China’s approval for the import of Pfizer’s new Covid-19 drug surprised many.

The National Medical Products Administration’s (NMPA) conditional approval for the Paxlovid came with unprecedented haste, especially given how bearish the country has been on foreign-made Covid-19 treatments. The green light came on Feb. 12, barely two months after the U.S. Food and Drug Administration signed off on it.